Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Still Disease Clear all

Conditions: Heart Defects, Congenital
Interventions: Clopidogrel, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Months and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 24 Months
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more

Conditions: Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 6
States / cities: Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 11
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more

Conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 0 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epilepsy, Partial
Interventions: Seletracetam (UCB44212); Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more

Conditions: Ischemic Cerebrovascular Accident
Interventions: hyperbaric oxygen chamber; Other
Lead sponsor: John Davidson; Other
Eligibility: 50 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions: anakinra, Placebo; Biological · Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more

Conditions: Obstructive Sleep Apnea, Sleepiness
Interventions: Active tPBM; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
Interventions: IL-1 Trap; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: questionnaire administration, computed tomography, radiation therapy treatment planning/simulation; Other · Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Erosive Esophagitis
Interventions: X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy; Drug
Lead sponsor: Cinclus Pharma Holding AB; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: rilonacept (IL-1 Trap), Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 4 Years to 20 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more

Search by objective public record fields.

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Rheumatology Patient Registry and Biorepository

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness

Interleukin-1 Trap to Treat Autoinflammatory Diseases

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)